#1 Clinical Trials Search in Europe

Abc-23B-116

This article discusses the ongoing clinical trials for V116, a new pneumococcal vaccine being developed by Merck & Co. Inc. The trials aim to assess the safety, tolerability, and immune response of V116 in various populations at increased risk for pneumococcal disease, including adults, children, and adolescents. These studies are important for understanding how well V116 protects against pneumococcal infections and its potential as a new preventive option.

Table of Contents

What is ABC-23B-116?

ABC-23B-116 is a new vaccine being developed to protect against pneumococcal disease. It is part of a larger vaccine called V116, which is a 21-valent pneumococcal conjugate vaccine[1]. This means it targets 21 different types (or serotypes) of pneumococcal bacteria. ABC-23B-116 specifically refers to one of the components in this vaccine that targets the 23B serotype of pneumococcus[2].

What is Pneumococcal Disease?

Pneumococcal disease is an infection caused by bacteria called Streptococcus pneumoniae, also known as pneumococcus. These bacteria can cause various types of illnesses, ranging from mild to severe. Some common pneumococcal infections include:

  • Pneumonia (infection of the lungs)
  • Ear infections
  • Sinus infections
  • Meningitis (infection of the covering of the brain and spinal cord)
  • Bacteremia (blood infection)

Pneumococcal disease can affect people of all ages, but it’s particularly dangerous for young children, older adults, and people with weakened immune systems or certain chronic health conditions[3].

How Does ABC-23B-116 Work?

ABC-23B-116 is a conjugate vaccine. This means it combines a part of the pneumococcal bacteria (specifically, a sugar molecule called a polysaccharide) with a protein that helps the immune system recognize and respond to the bacteria more effectively[1].

When you receive the vaccine, your immune system learns to recognize this specific part of the pneumococcus bacteria. If you’re later exposed to the real bacteria, your immune system can quickly recognize it and mount a defense, helping to prevent infection or reduce its severity[2].

Who is ABC-23B-116 For?

The V116 vaccine, which includes ABC-23B-116, is being studied in several groups of people:

  • Adults aged 18 to 64 who are at increased risk for pneumococcal disease[1]
  • Adults aged 50 years and older[2]
  • Children and adolescents with increased risk of pneumococcal disease[3]

People at increased risk for pneumococcal disease include those with certain medical conditions such as:

  • Diabetes
  • Chronic liver disease
  • Chronic lung disease (like COPD or asthma)
  • Chronic heart disease
  • Chronic kidney disease

Clinical Trials of ABC-23B-116

ABC-23B-116, as part of the V116 vaccine, is currently being studied in Phase 3 clinical trials. These are large-scale studies designed to confirm the safety and effectiveness of the vaccine. Some key points about these trials:

  • They are randomized, double-blind studies, which means participants are randomly assigned to receive either V116 or another pneumococcal vaccine, and neither the participants nor the researchers know who received which vaccine[1][2][3].
  • The studies are comparing V116 to existing pneumococcal vaccines (PCV15 + PPSV23 or PPSV23 alone)[1][2].
  • Researchers are looking at both the safety of the vaccine and how well it stimulates the immune system to produce antibodies against pneumococcal bacteria[1][2][3].

Potential Benefits and Side Effects

While the full results of the clinical trials are not yet available, researchers hope that V116 (including ABC-23B-116) will provide effective protection against pneumococcal disease, particularly for people at increased risk.

As with any vaccine, there may be side effects. The clinical trials are carefully monitoring for any adverse events. Common side effects of vaccines can include:

  • Pain, redness, or swelling at the injection site
  • Fatigue
  • Headache
  • Muscle pain
  • Fever

More serious side effects are rare but are being closely watched for in the clinical trials[1][2][3].

Conclusion

ABC-23B-116, as part of the V116 pneumococcal vaccine, represents a potentially important advancement in protecting against pneumococcal disease. While it’s still in the testing phase, the hope is that it will provide broader and more effective protection, especially for those at higher risk. As with any medical treatment, it’s important to discuss with your healthcare provider whether this vaccine might be appropriate for you or your child once it becomes available.

Aspect Details
Vaccine Name V116 (Pneumococcal 21-valent Conjugate Vaccine)
Manufacturer Merck & Co. Inc.
Study Populations Adults 18-64 years, Adults 50+ years, Children and adolescents at risk
Primary Objectives Safety, tolerability, and immunogenicity assessment
Key Measurements Adverse events, OPA GMTs, IgG GMCs, Proportion with ≥4-fold rise in antibodies
Administration 0.5 ml intramuscular injection
Comparison PPSV23 (23-valent pneumococcal polysaccharide vaccine)
Study Design Phase 3, randomized, double-blind, active comparator-controlled

FAQ

  • What is V116? V116 is a new pneumococcal vaccine being developed by Merck & Co. Inc. It is a 21-valent conjugate vaccine, which means it targets 21 different strains of pneumococcal bacteria.
  • Who is being studied in these clinical trials? The clinical trials are studying various groups at increased risk for pneumococcal disease, including adults aged 18-64, adults 50 years and older, and children and adolescents with certain health conditions.
  • What are the main goals of these studies? The main goals are to evaluate the safety and tolerability of V116, as well as its ability to stimulate an immune response (immunogenicity) in the study participants.
  • How is the vaccine administered? V116 is administered as an intramuscular injection, with a dose of 0.5 ml.
  • What are some of the health conditions that put people at higher risk for pneumococcal disease? Some conditions that increase risk include diabetes, chronic liver disease, chronic lung disease (such as COPD or asthma), chronic heart disease, and chronic kidney disease.

Ongoing Clinical Trials on Abc-23B-116

  • Study on the Safety and Immune Response of V116 Vaccine for Pneumococcal Disease in Adults Aged 50 and Older

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany Spain

  • Study on the Safety and Immune Response of V116 Vaccine in Children and Adolescents at Higher Risk for Pneumococcal Disease

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland France Poland Spain Sweden

  • Study on the V116 Vaccine for Adults Aged 18-64 at Increased Risk of Pneumococcal Infection

    Not recruiting

    1 1 1
    Investigated drugs:
    Poland

Glossary

  • Pneumococcal disease: Infections caused by Streptococcus pneumoniae bacteria, which can lead to pneumonia, bloodstream infections, or meningitis.
  • Conjugate vaccine: A type of vaccine that joins a weak antigen to a strong antigen to create a more powerful immune response.
  • Opsonophagocytic activity (OPA): A measure of the immune system's ability to kill bacteria with the help of antibodies and complement proteins.
  • Immunoglobulin G (IgG): The most common type of antibody in blood and other body fluids, which protects against bacterial and viral infections.
  • Geometric mean titer (GMT): A way to measure the average amount of antibodies in a group of people, useful for comparing immune responses.
  • Adverse event (AE): Any unfavorable or unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it is related to the treatment being studied.
  • Serotype: A distinct variation within a species of bacteria, identified by the immune system. V116 targets 21 different pneumococcal serotypes.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.

References

  1. http://clinicaltrials.eu/trial/study-on-the-v116-vaccine-for-adults-aged-18-64-at-increased-risk-of-pneumococcal-infection/
  2. http://clinicaltrials.eu/trial-id/2022-503144-40-00
  3. http://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-v116-vaccine-in-children-and-adolescents-at-higher-risk-for-pneumococcal-disease/